Novo Nordisk A/S (NYSE:NVO) Trading Down 2.6% on Analyst Downgrade

Shares of Novo Nordisk A/S (NYSE:NVO) dropped 2.6% during mid-day trading on Tuesday after TD Cowen downgraded the stock from a buy rating to a hold rating. TD Cowen now has a $42.00 price target on the stock. Novo Nordisk A/S traded as low as $38.18 and last traded at $38.7290. Approximately 19,945,510 shares changed hands during trading, a decline of 25% from the average daily volume of 26,434,695 shares. The stock had previously closed at $39.78.

A number of other research analysts have also weighed in on the company. CICC Research assumed coverage on Novo Nordisk A/S in a research report on Friday, January 9th. They set an “outperform” rating and a $73.50 price objective for the company. Weiss Ratings raised Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, February 5th. Argus restated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th. Finally, Citigroup assumed coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 27th. They issued a “neutral” rating on the stock. Four research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Novo Nordisk A/S has a consensus rating of “Hold” and a consensus target price of $49.93.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Deal with telehealth platform Hims & Hers ends a legal dispute and widens digital distribution of branded Ozempic and Wegovy, reducing litigation risk and opening a new consumer channel for prescriptions. Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit
• Positive Sentiment: Capital investment to expand production capacity in Ireland (~$506M) targets oral GLP‑1 manufacturing — a move to support global demand and reduce supply constraints. Novo expands manufacturing to support GLP-1 demand
• Positive Sentiment: Ongoing share repurchase program (part of up to DKK 15bn plan) supports capital returns and underpins shareholder value. Novo Nordisk share repurchase programme
• Neutral Sentiment: Recent quarterly results beat consensus on revenue and EPS, showing continued obesity-care growth — but management lowered FY2026 guidance, creating mixed near-term fundamentals. Earnings beat but guidance cut
• Negative Sentiment: FDA warning letter tied to a U.S. inspection and allegations of unreported semaglutide (Ozempic/Wegovy) side effects — reports cite cases including two deaths and a suicide — raising regulatory, reporting and reputational risk. FDA warns Novo Nordisk over unreported Ozempic side effects, deaths
• Negative Sentiment: Analysts and investors are increasingly worried about loss of exclusivity (LOE), U.S. price pressure and a less-differentiated pipeline versus rivals; TD Cowen downgraded NVO to hold and Citi kept neutral amid intensifying competition. Pipeline concerns and analyst downgrades
• Negative Sentiment: Competitive pressure: late‑stage data from rivals (e.g., Regeneron, Lilly) show similar weight‑loss efficacy with fewer GI side effects, threatening market share and pricing power for semaglutide products. GLP-1 competitive threat

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. PeakShares LLC purchased a new position in Novo Nordisk A/S in the 4th quarter worth about $491,000. Union Savings Bank purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at about $312,000. Mengis Capital Management Inc. boosted its holdings in shares of Novo Nordisk A/S by 303.2% during the 4th quarter. Mengis Capital Management Inc. now owns 66,694 shares of the company’s stock valued at $3,393,000 after acquiring an additional 50,154 shares during the last quarter. AG Campbell Advisory LLC bought a new stake in shares of Novo Nordisk A/S in the fourth quarter worth approximately $122,000. Finally, Rehmann Capital Advisory Group raised its holdings in shares of Novo Nordisk A/S by 33.6% during the fourth quarter. Rehmann Capital Advisory Group now owns 18,552 shares of the company’s stock valued at $944,000 after purchasing an additional 4,664 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Price Performance

The stock has a market capitalization of $172.92 billion, a PE ratio of 11.16 and a beta of 0.74. The firm’s fifty day moving average price is $51.18 and its two-hundred day moving average price is $52.24. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. The company had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. On average, equities analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Dividend Announcement

The company also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be issued a $1.2751 dividend. The ex-dividend date of this dividend is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s payout ratio is presently 23.63%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.